Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is currently in talks with Germany’s Carl Zeiss Meditec AG. In case they reach an agreement, Bausch & Lomb unit’s surgical products business will be sold off to Carl Zeiss Meditec AG.

Joe Papa, who is the Chief Executive for Valeant, has been doing a great job towards helping the company make the right steps in different fields. The biggest challenge they have been facing has been that of trying to repay a debt of about $30 billion, which was accumulated following a series of acquisitions.

The top executive while speaking to a number of reporters said that they would repay it in good time. When asked how that would happen, he said that the company was laying down a number of profit making strategies, which would help boost its revenues. Asides from that, the board had reached an agreement to sell off some of the assets since the company badly needed to forget about this debt and instead focus on development.

Some trusted sources have revealed that talks between the two top providers are ongoing. At the same time, other bidders continue to express their interest in the business. The company’s CEO has continued to assure investors that they are doing what is best for the company and the investors. There is no cause for alarm.

During a recent interview, some top analyst agreed that Valeant Pharmaceuticals is indeed one of those stocks that are really difficult to value. A regular company usually has stock price that reflects cash flow, top line growth or EPS. However, in Valeant’s case, the price is somehow determined by the probability of the provider not going bankrupt. It is a very uncomfortable position for any company to be and making it through this is going to require great intervention.

What positions the company in a place of power is its new management team. It has been rated as superb by top analysts. In just a few months, it was clear for anyone to see the capability of Paul Herendeen, who according to the company’s insiders helped it make major progress in terms of repaying the debt.